Blanket Purchase Agreement V797D70252-36E79722A0029
Award Date
11/1/22
Last Date to Order
10/31/25
Federal Agency
National Acquisition Center
Awardee
Gilead Sciences Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract to Asegua Therapeutics LLC, a subsidiary of the biopharmaceutical company Gilead Sciences Inc. The contract, valued at $33 million, is under GSA Schedule 61-IB for Pharmaceuticals and Drugs. This multiple-award IDV allows various federal agencies to purchase Gilead's comprehensive pharmaceutical portfolio, which includes critical medications such as Veklury (remdesivir) for COVID-19 treatment,...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer, to provide critical medications for the treatment of rare diseases such as pulmonary arterial hypertension. The $118.5 million BPA covers the period from August 2024 to August 2025 and allows the VA, Federal Bureau of Prisons, and other federal agencies to procure specialized drug therapies like...
This Blanket Purchase Agreement (BPA) is a single-award indefinite delivery vehicle (IDV) held by Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The BPA, valued at $123.5 million, was awarded by the Department of Veterans Affairs (VA) National Acquisition Center and is set to run through October 2025. The primary purpose of this BPA is to provide the VA with a streamlined procurement mechanism for the specialty...
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, to provide the drugs TEGSEDI and ORFADIN. The BPA, valued up to $11.75 million, covers the period from October 2021 through September 2025. Sobi, Inc. also holds a multiple award schedule contract with the VA valued at up to $78 million through July 2025 for pharmaceutical products under the Federal...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
The U.S. Department of Veterans Affairs (VA) awarded a $3.7 million Blanket Purchase Agreement (BPA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a large pharmaceutical manufacturer. The BPA allows VA medical facilities to place firm fixed price call orders for the oncology medications BALVERSA (erdafitinib) and Belzutifan (WELIREG) through July 2024. This streamlined procurement vehicle supports the VA's Veterans Health Administration (VHA) in maintaining a steady...
The U.S. Department of Veterans Affairs (VA) awarded a $10 million Blanket Purchase Agreement (BPA) to Servier Pharmaceuticals LLC, a for-profit pharmaceutical company, to provide the specialty oncology medications asparlas and oncaspar over a five-year period. This single-award BPA was issued against Servier's existing Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs. The VA has placed several fixed-price call orders against this BPA for delivery of asparlas and oncaspar...
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The single-award BPA (Contract #36E79724A0005) has a ceiling value of $5,500,000 and is effective from January 18, 2024 to September 19, 2024. It was awarded without the use of a set-aside and enables the...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to United Therapeutics Corporation, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The BPA has a ceiling value of $207,127,385 and a performance period extending through April 2026. It allows the VA to procure specialized pharmaceutical products from United Therapeutics' portfolio, including Orenitram, Remodulin, Tyvaso,...
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America Inc. in July 2020. The $19,472,334.90 BPA, which falls under Takeda's General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract, facilitates the streamlined procurement of critical specialty pharmaceutical products for the VA healthcare system. Key products under this BPA include CINRYZE and KALBITOR for...